Key Points
The injectable tirzepatide is indicated for type 2 diabetes with the additional benefit of causing weight loss, and has been a global smash hit since its launch in 2022...
It goes under the brand name Mounjaro for diabetes, and Zepbound for weight loss...
The USFDA approval for Zepbound comes for adults with obesity (with a BMI of 30 kg/square metre or greater), or those who are overweight (with a BMI of 27 kg/square metre or greater) and also have weight-related medical problems such as hypertension, dyslipidemia (high cholesterol), type 2 diabetes mellitus, obstructive sleep apnoea or cardiovascular disease, to lose weight and keep it off...
Lilly said in a statement that the USFDA approval was based on results from the phase 3 trials, which involved 2,539 adults with obesity, or excess weight and weight-related medical problems not including diabetes, adding that use of the drug may be associated with gastrointestinal side-effects...
According to the company, Zepbound is expected to be available in the US by the end of the year in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) at a list price of $1,059.87 (Rs 88,252), which is approximately 20 percent lower than a semaglutide 2.4-mg injection for weight loss...
You might be interested in
Roche enters obesity drugs race with $2.7 bln Carmot deal
04, Dec, 23The race to grab a slice of the lucrative market for obesity treatments is heating up among drugmakers, with Swiss company Roche (ROG.S) becoming one of the latest entrants following its $2.7 billion deal to buy Carmot Therapeutics (CRMO.O).
The next game-changing weight loss drug just moved closer to FDA approval
27, Apr, 23In a new study, patients on tirzepatide (Mounjaro) lost nearly 16% of their body weight in 16 months.
Mounjaro: Weight loss drug suppresses appetite, awaits FDA approval
17, Mar, 23Tirzepatide, sold as Mounjaro, is a diabetes medication being considered for use to treat obesity, like the related drug semaglutide.
Has a 'magical' weight loss drug finally arrived? Hopes soar with US firm's never-before-seen results
29, Jun, 23Patients who got a weekly injection of the experimental anti-obesity drug retatrutide lost up to 24 per cent of their body weight in 48 weeks, show phase-2 trials published this week.
Avoid weight gain after Ozempic with 'maintenance dose': Doctor
25, Mar, 23Weight gain is a common experience among people who stop taking Ozempic. One doctor is experimenting with tapering off slowly to keep weight low.
More evidence needed on Lilly's weight loss drug, UK watchdog says
27, Jun, 23UK's drug cost-effectiveness watchdog on Tuesday did not recommend Eli Lilly's weight loss drug for adults with diabetes, saying more evidence was needed before it could be used by the National Health Service (NHS).
Tirzepatide approved for weight loss, stronger than semaglutide
08, Nov, 23Mounjaro is a stronger drug than Ozempic. Now, there's a version of the drug available for patients who aren't diabetic.
Eli Lilly's Zepbound: Here's what to know about new obesity drug approved by FDA
09, Nov, 23The US Food and Drug Administration has approved a new obesity drug- Zepbound
Weight loss from Eli Lilly’s Zepbound reversed slowly after treatment stopped
11, Dec, 23People who stopped taking Eli Lilly & Co.’s Zepbound after about eight months regained half the weight they’d lost a year later, as per a study. | Health
Why People Stop Using Drugs Like Ozempic
07, Jul, 23Drugs like semaglutide—better known as Ozempic or Wegovy—could be lifelong treatments for obesity, but what little data scientists have suggests that people don't stick with them for long.